Patient-Centric Approaches: Revolutionizing Rare Disease Drug Research

Abhishek      Verma; Ankit      Awasthi

Abozaid G.M.; Kerr K.; McKnight A.; Al-Omar H.A.; Criteria to define rare diseases and orphan drugs: A systematic review protocol. BMJ Open 2022,12(7),e062126 10.1136/bmjopen-2022-062126 35906057 Postma M.J.; Noone D.; Rozenbaum M.H.; Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Orphanet J Rare Dis 2022,17(1),157 10.1186/s13023-022-02283-z 35382853 Keikhosrokiani P.; Mustaffa N.; Zakaria N.; Success factors in developing iHeart as a patient-centric healthcare system: A multi-group analysis. Telemat Inform 2018,35(4),753-775 10.1016/j.tele.2017.11.006 Uymaz A.O.; The shift from disease-centric to patient-centric healthcare: Assessing physicians’ intention to use AI doctors. EnvironSoc Psychol 2024,9(4),1944 Aminabee S.; The future of healthcare and patient-centric care: Digital innovations, trends, and predictions Emerging Technologies for Health Literacy and Medical Practice 2024,240-262 10.4018/979-8-3693-1214-8.ch012 Sudhakar P.; Wellens J.; Verstockt B.; Ferrante M.; Sabino J.; Vermeire S.; Holistic healthcare in inflammatory bowel disease: Time for patient-centric approaches? Gut 2023,72(1),192-204 10.1136/gutjnl-2022-328221 36171081 Halley M.C.; Smith H.S.; Ashley E.A.; Goldenberg A.J.; Tabor H.K.; A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States. Nat Genet 2022,54(3),219-222 10.1038/s41588-022-01027-w 35256804 Aiuti A.; Pasinelli F.; Naldini L.; Ensuring a future for gene therapy for rare diseases. Nat Med 2022,28(10),1985-1988 10.1038/s41591-022-01934-9 35970921 Applequist J.; Burroughs C.; Merkel P.A.; Direct-to-Consumer recruitment methods via traditional and social media to aid in research accrual for clinical trials for rare diseases: Comparative analysis study. J Med Internet Res 2023,25,e39262 10.2196/39262 36917158 Balkhi B.; Almuaither A.; Alqahtani S.; Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union. Saudi Pharm J 2023,31(9),101738 10.1016/j.jsps.2023.101738 37638213 Timpe C.; Stegemann S.; Barrett A.; Mujumdar S.; Challenges and opportunities to include patient‐centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol 2020,86(10),2020-2027 10.1111/bcp.14388 32441052 Epps C.; Bax R.; Croker A.; Global regulatory and public health initiatives to advance pediatric drug development for rare diseases. Ther Innov Regul Sci 2022,56(6),964-975 10.1007/s43441-022-00409-w 35471559 Vreman R.A.; de Ruijter A.S.; Zawada A.; Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discov Today 2020,25(7),1223-1231 10.1016/j.drudis.2020.04.012 32344040 Feng J.; Gao Z.; Shi Z.; Wang Y.; Li S.; Patient-reported outcomes in Gaucher’s disease: A systematic review. Orphanet J Rare Dis 2023,18(1),244 10.1186/s13023-023-02844-w 37626429 Nguyen C.Q.; Alba-Concepcion K.; Palmer E.E.; Scully J.L.; Millis N.; Farrar M.A.; The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: A narrative review. Orphanet J Rare Dis 2022,17(1),167 10.1186/s13023-022-02317-6 35436886 Zuccato M.; Shilling D.; Fajgenbaum D.C.; The collaborative network approach: A model for advancing patient-centric research for Castleman disease and other rare diseases. Emerg Top Life Sci 2019,3(1),97-105 10.1042/ETLS20180178 33523193 Bellgard M.I.; Sleeman M.W.; Guerrero F.D.; Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes. Health Policy Technol 2014,3(4),325-335 10.1016/j.hlpt.2014.08.007 Flatau T.; Greenfield J.; Dickie B.; Rayner O.; Matthews H.; Wise J.; Medical research charities and biopharmaceutical companies as partners in patient-centred RandD. Pharmaceut Med 2022,36(5),279-286 10.1007/s40290-022-00442-y 35953655 Harnish JM; Li L; Rogic S; ModelMatcher: A scientist‐centric online platform to facilitate collaborations between stakeholders of rare and undiagnosed disease research. Hum Mutat 2022,43(6),humu.24364 10.1002/humu.24364 35224820 Watts G.F.; Gidding S.S.; Mata P.; Familial hypercholesterolaemia: Evolving knowledge for designing adaptive models of care. Nat Rev Cardiol 2020,17(6),360-377 10.1038/s41569-019-0325-8 31974482 Alcalde-Rubio L.; Hernández-Aguado I.; Parker L.A.; Bueno-Vergara E.; Chilet-Rosell E.; Gender disparities in clinical practice: Are there any solutions? Scoping review of interventions to overcome or reduce gender bias in clinical practice. Int J Equity Health 2020,19(1),166 10.1186/s12939-020-01283-4 32962719 Halley M.C.; Halverson C.M.E.; Tabor H.K.; Goldenberg A.J.; Rare disease, advocacy and justice: Intersecting disparities in research and clinical care. Am J Bioeth 2023,23(7),17-26 10.1080/15265161.2023.2207500 37204146 Brandt M.; Johannsen L.; Inhestern L.; Bergelt C.; Parents as informal caregivers of children and adolescents with spinal muscular atrophy: A systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs. Orphanet J Rare Dis 2022,17(1),274 10.1186/s13023-022-02407-5 35854387 Ni Q.; Chen X.; Zhang P.; Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians. Orphanet J Rare Dis 2022,17(1),129 10.1186/s13023-022-02279-9 35313924 Sharma R.; Ahmed S.; Campagnari J.; Huff W.; Lloyd L.; Embedding patient-centricity by collaborating with patients to transform the rare disease ecosystem. Pharmaceut Med 2023,37(4),265-273 10.1007/s40290-023-00474-y 37142887 Huml R.A.; Dawson J.; Bailey M.; Accelerating rare disease drug development: Lessons learned from muscular dystrophy patient advocacy groups. Ther Innov Regul Sci 2021,55(2),370-377 10.1007/s43441-020-00221-4 32974874 Monaco L.; Zanello G.; Baynam G.; Research on rare diseases: Ten years of progress and challenges at IRDiRC. Nat Rev Drug Discov 2022,21(5),319-320 10.1038/d41573-022-00019-z 35079160 Smith J.; Damm K.; Hover G.; Chien J.; Lessons from an experiential approach to patient community engagement in rare disease. Clin Ther 2021,43(2),421-429 10.1016/j.clinthera.2020.12.002 33375998 Bensbih S.; Souadka A.; Diez A.G.; Bouksour O.; Patient centered care: Focus on low and middle income countries and proposition of new conceptual model. J Med Surg Res 2020,7,755-763 10.46327/msrjg.1.000000000000168 Khanna S.; Srivastava S.; Patient-centric ethical frameworks for privacy, transparency, and bias awareness in deep learning-based medical systems. Appl Res Artif Intell Cloud Comput 2020,3(1),16-35 Beier K.; Schweda M.; Schicktanz S.; Taking patient involvement seriously: A critical ethical analysis of participatory approaches in data-intensive medical research. BMC Med Inform Decis Mak 2019,19(1),90 10.1186/s12911-019-0799-7 31023321 Pergher I.; Brandolf V.P.; Pacheco D.A.J.; Vaccaro G.L.R.; A patient-centric approach to improve health care services. Cogent Busi Manag 2016,3(1),1227232 10.1080/23311975.2016.1227232 Wan TT; Wan HS; Predictive analytics with a transdisciplinary framework in promoting patient-centric care of polychronic conditions: Trends, challenges, and solutions. AI 2023,4(3),482-90 10.3390/ai4030026 Sharma N.; Patient centric approach for clinical trials: Current trend and new opportunities. Perspect Clin Res 2015,6(3),134-138 10.4103/2229-3485.159936 26229748 de Lorenzo F.; Apostolidis K.; The European Cancer Patient Coalition and its central role in connecting stakeholders to advance patient‐centric solutions in the mission on cancer. Mol Oncol 2019,13(3),653-666 10.1002/1878-0261.12448 30657631

Cite As

Infectious Disorders - Drug Targets

Patient-Centric Approaches: Revolutionizing Rare Disease Drug Research